New Screening/Surveillance Approaches For BE May Uncover More Cancers

Improved means for preventing esophageal cancer, including nonendoscopic screening and molecular surveillance for ...

APRIL 21, 2025

Closing the Door on Barrett’s: The Critical Role of Reflux Control in EET Outcomes

Despite two decades of progress in ablation techniques, the incidence of esophageal cancer has remained largely ...

MARCH 21, 2025

Spray Cryotherapy Expands Treatment Options For Challenging Esophageal Cancer Cases

Cryotherapy has emerged as a promising treatment option for various stages of esophageal cancer, offering a ...

MARCH 19, 2025

FDA Approves Opdivo Qvantig for Subcutaneous Injection

The FDA approved nivolumab plus hyaluronidase (Opdivo Qvantig, Bristol Myers Squibb) for an array of GI cancers.

JANUARY 8, 2025

BE Indefinite for Dysplasia Requires Close Follow-up in Year After Diagnosis

Management of Barrett’s esophagus patients who have tissue that is indefinite for dysplasia hasn’t ...

OCTOBER 23, 2024

Latest Updates on Esophageal Fluorescence-Guided Surgery

Esophageal fluorescence-guided surgery has rapidly gained ground.

SEPTEMBER 12, 2024

Chemotherapy Before and After Surgery Benefits Patients With Resectable Esophageal Cancer

Chemotherapy before and after surgery for locally advanced esophageal adenocarcinoma improved survival relative to ...

AUGUST 7, 2024

Barrett’s Esophagus: Guideline Interpretation and Application to Management

This review provides an update on the recently published guidelines from the ACG and AGA on the diagnosis and ...

AUGUST 1, 2024

Traction Found to Help Margins in ESD of Esophageal Cancer

Use of traction during endoscopic submucosal dissection for T1b esophageal cancer is associated with negative ...

JULY 10, 2024

RFA Associated With Lower Risk of EAC in BE Patients

Radiofrequency ablation treatment is effective in reducing the likelihood of progression to cancer, according to ...

MAY 19, 2024

Research Identifies Distinct Patterns and Predictors of PPI Adherence in Patients With Barrett’s Esophagus

Although PPIs are a mainstay in preventing cancer in patients with Barrett’s esophagus, 56% of these patients ...

APRIL 24, 2024

Tevimbra Approved for Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemo

The FDA approved tislelizumab-jsgr as monotherapy for certain adult patients with esophageal squamous cell ...

MARCH 19, 2024